Amanda L Blackford1, Marcia Irene Canto1,2, Alison P Klein1,3, Ralph H Hruban1,3, Michael Goggins1,2,3. 1. Affiliations of authors: Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA. 2. Department of Medicine, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA. 3. Departments of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Abstract
BACKGROUND: Rapid access to pancreatic imaging and regular pancreatic surveillance may help identify stage I pancreatic cancer. We investigated recent trends in the stage of newly diagnosed pancreatic ductal adenocarcinoma (PDACs), age at diagnosis, and survival. METHODS: Trends in age-adjusted incidence of stage IA PDAC between 2004 and 2016 were determined from the National Cancer Institute's Surveillance, Epidemiology and End Results database. All tests were two-sided. RESULTS: The incidence of stage IA PDAC cases diagnosed increased statistically significantly from 2004 to 2016 (annual percent change = 14.5, 95% confidence interval [CI] = 11.4 to 17.7; P < .001). During the study period, average age at diagnosis for stage IA and IB casesAQ3 declined by 3.5 years (95% CI = 1.2 to 5.9; P = .004) and 5.5 years (95% CI = 3.4 to 7.6; P < .001), whereas average age increased for higher-stage cases (by 0.6 to 1.4 years). Among stage IA cases, the proportion of blacks was smaller (10.2% vs 12.5%), and the proportion of other non-Caucasians was higher compared with higher-stage cases (11.9% vs 8.4%; P < .001). Stage IA cases were more likely to carry insurance (vs Medicaid or none) than higher-stage cases (cases aged younger than 65 years; odds ratio = 2.45, 95% CI = 1.96 to 3.06; P < .001). The 5-year overall survival for stage IA PDAC improved from 44.7% (95% CI = 31.4 to 63.7) in 2004 to 83.7% (95% CI = 78.6% to 89.2%) in 2012; 10-year survival improved from 36.7% (95% CI = 24.1 to 55.8) in 2004 to 49.0% (95% CI = 37.2% to 64.6%) in 2007. CONCLUSIONS: In recent years, the proportion of patients diagnosed with stage IA PDAC has increased, their average age at diagnosis has decreased, and their overall survival has improved. These trends may be the result of improved early diagnosis and early detection.
BACKGROUND: Rapid access to pancreatic imaging and regular pancreatic surveillance may help identify stage I pancreatic cancer. We investigated recent trends in the stage of newly diagnosed pancreatic ductal adenocarcinoma (PDACs), age at diagnosis, and survival. METHODS: Trends in age-adjusted incidence of stage IA PDAC between 2004 and 2016 were determined from the National Cancer Institute's Surveillance, Epidemiology and End Results database. All tests were two-sided. RESULTS: The incidence of stage IA PDAC cases diagnosed increased statistically significantly from 2004 to 2016 (annual percent change = 14.5, 95% confidence interval [CI] = 11.4 to 17.7; P < .001). During the study period, average age at diagnosis for stage IA and IB casesAQ3 declined by 3.5 years (95% CI = 1.2 to 5.9; P = .004) and 5.5 years (95% CI = 3.4 to 7.6; P < .001), whereas average age increased for higher-stage cases (by 0.6 to 1.4 years). Among stage IA cases, the proportion of blacks was smaller (10.2% vs 12.5%), and the proportion of other non-Caucasians was higher compared with higher-stage cases (11.9% vs 8.4%; P < .001). Stage IA cases were more likely to carry insurance (vs Medicaid or none) than higher-stage cases (cases aged younger than 65 years; odds ratio = 2.45, 95% CI = 1.96 to 3.06; P < .001). The 5-year overall survival for stage IA PDAC improved from 44.7% (95% CI = 31.4 to 63.7) in 2004 to 83.7% (95% CI = 78.6% to 89.2%) in 2012; 10-year survival improved from 36.7% (95% CI = 24.1 to 55.8) in 2004 to 49.0% (95% CI = 37.2% to 64.6%) in 2007. CONCLUSIONS: In recent years, the proportion of patients diagnosed with stage IA PDAC has increased, their average age at diagnosis has decreased, and their overall survival has improved. These trends may be the result of improved early diagnosis and early detection.
Authors: Marcia Irene Canto; Jose Alejandro Almario; Richard D Schulick; Charles J Yeo; Alison Klein; Amanda Blackford; Eun Ji Shin; Abanti Sanyal; Gayane Yenokyan; Anne Marie Lennon; Ihab R Kamel; Elliot K Fishman; Christopher Wolfgang; Matthew Weiss; Ralph H Hruban; Michael Goggins Journal: Gastroenterology Date: 2018-05-24 Impact factor: 22.682
Authors: Ahmed Jamal; Brian A King; Linda J Neff; Jennifer Whitmill; Stephen D Babb; Corinne M Graffunder Journal: MMWR Morb Mortal Wkly Rep Date: 2016-11-11 Impact factor: 17.586
Authors: Jin He; Nita Ahuja; Martin A Makary; John L Cameron; Frederic E Eckhauser; Michael A Choti; Ralph H Hruban; Timothy M Pawlik; Christopher L Wolfgang Journal: HPB (Oxford) Date: 2013-03-08 Impact factor: 3.647
Authors: Stefano Crippa; Claudio Bassi; Roberto Salvia; Giuseppe Malleo; Giovanni Marchegiani; Vinciane Rebours; Philippe Levy; Stefano Partelli; Shadeah L Suleiman; Peter A Banks; Nazir Ahmed; Suresh T Chari; Carlos Fernández-Del Castillo; Massimo Falconi Journal: Gut Date: 2016-01-07 Impact factor: 23.059
Authors: Alison P Klein; Kieran A Brune; Gloria M Petersen; Michael Goggins; Anne C Tersmette; G Johan A Offerhaus; Constance Griffin; John L Cameron; Charles J Yeo; Scott Kern; Ralph H Hruban Journal: Cancer Res Date: 2004-04-01 Impact factor: 12.701
Authors: Lei Huang; Lina Jansen; Yesilda Balavarca; Esther Molina-Montes; Masoud Babaei; Lydia van der Geest; Valery Lemmens; Liesbet Van Eycken; Harlinde De Schutter; Tom B Johannesen; Claus W Fristrup; Michael B Mortensen; Maja Primic-Žakelj; Vesna Zadnik; Nikolaus Becker; Thilo Hackert; Margit Mägi; Tiziana Cassetti; Romano Sassatelli; Robert Grützmann; Susanne Merkel; Ana F Gonçalves; Maria J Bento; Péter Hegyi; Gábor Lakatos; Andrea Szentesi; Michel Moreau; Tony van de Velde; Annegien Broeks; Milena Sant; Pamela Minicozzi; Vincenzo Mazzaferro; Francisco X Real; Alfredo Carrato; Xavier Molero; Marc G Besselink; Núria Malats; Markus W Büchler; Petra Schrotz-King; Hermann Brenner Journal: Gut Date: 2017-11-20 Impact factor: 23.059
Authors: Paolo G Gobbi; Manuela Bergonzi; Mario Comelli; Lara Villano; Donatella Pozzoli; Alessandro Vanoli; Paolo Dionigi Journal: Cancer Epidemiol Date: 2013-01-29 Impact factor: 2.984
Authors: Hans Vasen; Isaura Ibrahim; Carmen Guillen Ponce; Emily P Slater; Elvira Matthäi; Alfredo Carrato; Julie Earl; Kristin Robbers; Anneke M van Mil; Thomas Potjer; Bert A Bonsing; Wouter H de Vos Tot Nederveen Cappel; Wilma Bergman; Martin Wasser; Hans Morreau; Günter Klöppel; Christoph Schicker; Martin Steinkamp; Jens Figiel; Irene Esposito; Evelina Mocci; Enrique Vazquez-Sequeiros; Alfonso Sanjuanbenito; Maria Muñoz-Beltran; José Montans; Peter Langer; Volker Fendrich; Detlef K Bartsch Journal: J Clin Oncol Date: 2016-04-25 Impact factor: 44.544
Authors: Makoto Kawamoto; Shiro Kohi; Toshiya Abe; Mohamad Dbouk; Anne Macgregor-Das; Chiho Koi; Ki-Byung Song; Michael Borges; Ryo Sugimine; Daniel Laheru; Ralph H Hruban; Nicholas Roberts; Alison P Klein; Michael Goggins Journal: Int J Cancer Date: 2021-12-06 Impact factor: 7.396
Authors: Shiro Kohi; Anne Macgregor-Das; Mohamad Dbouk; Takeichi Yoshida; Miguel Chuidian; Toshiya Abe; Michael Borges; Anne Marie Lennon; Eun Ji Shin; Marcia Irene Canto; Michael Goggins Journal: Clin Gastroenterol Hepatol Date: 2020-11-05 Impact factor: 11.382
Authors: Bryson W Katona; Jessica M Long; Nuzhat A Ahmad; Sara Attalla; Angela R Bradbury; Erica L Carpenter; Dana F Clark; Gillain Constantino; Koushik K Das; Susan M Domchek; Christina Dudzik; Jessica Ebrahimzadeh; Gregory G Ginsberg; Jordan Heiman; Michael L Kochman; Kara N Maxwell; Danielle B McKenna; Jacquelyn Powers; Payal D Shah; Kirk J Wangensteen; Anil K Rustgi Journal: Cancer Prev Res (Phila) Date: 2021-08-02
Authors: Johannes F Fahrmann; C Max Schmidt; Xiangying Mao; Ehsan Irajizad; Maureen Loftus; Jinming Zhang; Nikul Patel; Jody Vykoukal; Jennifer B Dennison; James P Long; Kim-Anh Do; Jianjun Zhang; John A Chabot; Michael D Kluger; Fay Kastrinos; Lauren Brais; Ana Babic; Kunal Jajoo; Linda S Lee; Thomas E Clancy; Kimmie Ng; Andrea Bullock; Jeanine Genkinger; Michele T Yip-Schneider; Anirban Maitra; Brian M Wolpin; Samir Hanash Journal: Gastroenterology Date: 2020-12-14 Impact factor: 22.682
Authors: Bryson W Katona; Randall E Brand; Marcia I Canto; Amitabh Chak; James J Farrell; Fay Kastrinos; Anil K Rustgi; Elena M Stoffel; Sapna Syngal; Michael Goggins Journal: Cancer Prev Res (Phila) Date: 2021-10
Authors: Barbara Kenner; Suresh T Chari; David Kelsen; David S Klimstra; Stephen J Pandol; Michael Rosenthal; Anil K Rustgi; James A Taylor; Adam Yala; Noura Abul-Husn; Dana K Andersen; David Bernstein; Søren Brunak; Marcia Irene Canto; Yonina C Eldar; Elliot K Fishman; Julie Fleshman; Vay Liang W Go; Jane M Holt; Bruce Field; Ann Goldberg; William Hoos; Christine Iacobuzio-Donahue; Debiao Li; Graham Lidgard; Anirban Maitra; Lynn M Matrisian; Sung Poblete; Laura Rothschild; Chris Sander; Lawrence H Schwartz; Uri Shalit; Sudhir Srivastava; Brian Wolpin Journal: Pancreas Date: 2021-03-01 Impact factor: 3.243
Authors: José S Enriquez; Yan Chu; Shivanand Pudakalakatti; Kang Lin Hsieh; Duncan Salmon; Prasanta Dutta; Niki Zacharias Millward; Eugene Lurie; Steven Millward; Florencia McAllister; Anirban Maitra; Subrata Sen; Ann Killary; Jian Zhang; Xiaoqian Jiang; Pratip K Bhattacharya; Shayan Shams Journal: JMIR Med Inform Date: 2021-06-17
Authors: Ying Liu; Sukhwinder Kaur; Ying Huang; Johannes F Fahrmann; Jo Ann Rinaudo; Samir M Hanash; Surinder K Batra; Aatur D Singhi; Randall E Brand; Anirban Maitra; Brian B Haab Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-06-12 Impact factor: 4.254